Testing BCG treatment for bladder cancer after full tumor removal
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your bladder cancer is non-muscle invasive (stage Ta or T1) and has been completely removed by surgery, with confirmed pathology within 45 days.
- Your cancer is intermediate- or high-risk, and it was diagnosed within 45 days of joining the study.
- If your cancer is T1: scans (CT or MRI) show no spread to distant areas, and you must have had a repeat bladder surgery (repeat TURBT) with results reviewed within the required time window.
- You can do study activities and are able to take part (ECOG 0–2) and your blood/organ tests are high enough.
- You have not previously had bladder BCG treatments or certain other bladder cancer types, and you are not currently getting other cancer therapies during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a newer way to remove bladder tumors (called ERBT) combined with BCG, a standard immunotherapy placed in the bladder, for people with bladder cancer that is not too advanced. The goal is to see if this combination helps reduce the chance of the cancer coming back.
This study tries to predict whether BCG treatment will work for people with certain early-stage bladder cancers. It may help doctors better choose and monitor BCG for similar patients in the future.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
This study looks at how the bladder reacts to a standard treatment called BCG, which is given after surgery for early-stage bladder cancer. By checking the tissue and urine before treatment, the study aims to understand if the bladder is ready for BCG therapy, which could help improve outcomes.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.